Deloitte, Vineti to join platforms to support personalized medicine

A consultancy and cloud-based platform company plan to work together to support life science researchers access to emerging cellular therapies.

Deloitte and Vineti have entered an agreement to collaborate to assist life science innovators by integrating and scaling their respective supply chain and patient engagement platforms.

The move is expected to advance efforts, through the use of digital technology, to increase access to next-generation therapies for patients. The move comes as there is increased interest in individualized medicine, in which the patient is a key part of determining the therapeutic process.

Vineti has a cell and gene therapy platform that serves as a digital “platform of record” for individualized therapies. Deloitte brings its convergeHEALTH Patient Connect platform, which it says streamlines and improves patient and health system engagement.



The companies say the combined approach can offer a one-stop solution to support life sciences innovators and healthcare professionals with the information systems to enable them to deliver personalized medicine, and then expand the role of personalized medicines in mainstream healthcare.

"The advancement of truly personalized therapies reinforces not just the belief but the practice that the patient is at the center of therapeutic production, delivery and support," says Amy DuRoss, CEO and co-founder of Vineti. "We are looking for opportunities where we can integrate our offerings with the ConvergeHEALTH Patient Connect platform. This relationship will lead to holistic end-to-end services that connect automated supply chain workflows with a new level of support to the broader ecosystem and to patients."

By working with Vineti and ConvergeHEALTH by Deloitte, life sciences innovators will be able to scale their personalized therapies, connect with even more health care providers, and provide more therapies to more patients than ever before.